Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Change from baseline to 6 months for TSQM Effectiveness, Side Effects and Convenience subscale scores

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

  GA to fingolimod Remaining on GA IM IFN beta-1a to fingolimod Remaining on IM IFN beta-1a SC IFN beta-1a to fingolimod Remaining on SC IFN beta-1a IFN beta-1b to fingolimod Remaining on IFN beta-1b
(n = 262) (n = 74) (n = 205) (n = 48) (n = 196) (n = 58) (n = 125) (n = 39)
Effectiveness 12.16 ± 1.49 0.62 ± 2.76 13.31 ± 1.48 1.37 ± 3.13 15.07 ± 1.65 1.62 ± 3.02 17.59 ± 2.06 0.68 ± 3.62
Side effects 9.25 ± 1.41 4.47 ± 2.64 30.62 ± 1.56 6.56 ± 3.27 27.83 ± 1.43 -0.42 ± 2.61 21.50 ± 1.88 -1.24 ± 3.30
Convenience 38.01 ± 0.80 3.11 ± 1.49 43.83 ± 0.94 5.70 ± 1.97 42.36 ± 1.02 1.66 ± 1.87 41.57 ± 1.15 1.31 ± 2.04
  1. Values are displayed as least-squares means ± standard errors. p <0.001 for all comparisons; italics = non-significant result.
  2. GA, glatiramer acetate; IFN, interferon; IM, intramuscular; SC, subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.
Back to article page